Sareum’s FY22 results (to end-June 2022) provided both a financial and operational update on the company’s progress with its developmental pipeline. Encouraging progress has been made with SDC-1801 and the company has filed an exploratory clinical trial application (CTA) to initiate a UK-based Phase Ia/b study. Subject to regulatory approval, management intends for Phase Ia of the trial to commence in Q4 of CY22. Additionally, the company continues to progress its preclinical pipeline through th ....
25 Oct 2022
Sareum Holdings - SDC-1801 poised for the clinic
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Sareum Holdings - SDC-1801 poised for the clinic
Sareum Holdings plc (SAR:LON) | 24.2 -0.6 (-9.3%) | Mkt Cap: 24.6m
- Published:
25 Oct 2022 -
Author:
Soo Romanoff -
Pages:
3
Sareum’s FY22 results (to end-June 2022) provided both a financial and operational update on the company’s progress with its developmental pipeline. Encouraging progress has been made with SDC-1801 and the company has filed an exploratory clinical trial application (CTA) to initiate a UK-based Phase Ia/b study. Subject to regulatory approval, management intends for Phase Ia of the trial to commence in Q4 of CY22. Additionally, the company continues to progress its preclinical pipeline through th ....